The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

UK stocks are moving in a tight band Wednesday morning with investors largely focusing on earnings updates, and digesting the data on ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...

GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

Final investment decisions had been made for the Tarbert Next (LON: NXT) Generation biopower station in Co Kerry and the ...